Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 5
2020 8
2021 1
2022 4
2023 1
2024 4
2025 5
2026 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

30 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: NCT02971748
Page 1
Clinical and Biomarker Findings of Neoadjuvant Pembrolizumab and Carboplatin Plus Docetaxel in Triple-Negative Breast Cancer: NeoPACT Phase 2 Clinical Trial.
Sharma P, Stecklein SR, Yoder R, Staley JM, Schwensen K, O'Dea A, Nye L, Satelli D, Crane G, Madan R, O'Neil MF, Wagner J, Larson KE, Balanoff C, Kilgore L, Phadnis MA, Godwin AK, Salgado R, Khan QJ, O'Shaughnessy J. Sharma P, et al. JAMA Oncol. 2024 Feb 1;10(2):227-235. doi: 10.1001/jamaoncol.2023.5033. JAMA Oncol. 2024. PMID: 37991778 Free PMC article. Clinical Trial.
IMPORTANCE: Addition of pembrolizumab to anthracycline-based chemotherapy improves pathologic complete response (pCR) and event-free survival (EFS) in triple-negative breast cancer (TNBC). ...CONCLUSIONS AND RELEVANCE: The findings of the phase 2 …
IMPORTANCE: Addition of pembrolizumab to anthracycline-based chemotherapy improves pathologic complete response (pCR) and event-free …
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial.
Nanda R, Liu MC, Yau C, Shatsky R, Pusztai L, Wallace A, Chien AJ, Forero-Torres A, Ellis E, Han H, Clark A, Albain K, Boughey JC, Jaskowiak NT, Elias A, Isaacs C, Kemmer K, Helsten T, Majure M, Stringer-Reasor E, Parker C, Lee MC, Haddad T, Cohen RN, Asare S, Wilson A, Hirst GL, Singhrao R, Steeg K, Asare A, Matthews JB, Berry S, Sanil A, Schwab R, Symmans WF, van 't Veer L, Yee D, DeMichele A, Hylton NM, Melisko M, Perlmutter J, Rugo HS, Berry DA, Esserman LJ. Nanda R, et al. JAMA Oncol. 2020 May 1;6(5):676-684. doi: 10.1001/jamaoncol.2019.6650. JAMA Oncol. 2020. PMID: 32053137 Free PMC article. Clinical Trial.
DESIGN, SETTING, AND PARTICIPANTS: The I-SPY2 study is an ongoing open-label, multicenter, adaptively randomized phase 2 platform trial for high-risk, stage II/III breast cancer, evaluating multiple investigational arms in parallel. ...Patients with ER …
DESIGN, SETTING, AND PARTICIPANTS: The I-SPY2 study is an ongoing open-label, multicenter, adaptively randomized phase 2 platf …
Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial.
Radovich M, Jiang G, Hancock BA, Chitambar C, Nanda R, Falkson C, Lynce FC, Gallagher C, Isaacs C, Blaya M, Paplomata E, Walling R, Daily K, Mahtani R, Thompson MA, Graham R, Cooper ME, Pavlick DC, Albacker LA, Gregg J, Solzak JP, Chen YH, Bales CL, Cantor E, Shen F, Storniolo AMV, Badve S, Ballinger TJ, Chang CL, Zhong Y, Savran C, Miller KD, Schneider BP. Radovich M, et al. JAMA Oncol. 2020 Sep 1;6(9):1410-1415. doi: 10.1001/jamaoncol.2020.2295. JAMA Oncol. 2020. PMID: 32644110 Free PMC article. Clinical Trial.
IMPORTANCE: A significant proportion of patients with early-stage triple-negative breast cancer (TNBC) are treated with neoadjuvant chemotherapy. Sequencing of circulating tumor DNA (ctDNA) after surgery, along with enumeration of circulating tumor cells (CTC …
IMPORTANCE: A significant proportion of patients with early-stage triple-negative breast cancer (TNBC) are treated with neoadj …
A Phase Ib Study of Sapacitabine and Olaparib in Patients with BRCA1/2-Mutated Metastatic Breast Cancer.
Lynce F, Graham N, Kochupurakkal BS, Nguyen H, Bychkovsky B, Poorvu PD, Attaya V, Davis R, DiLullo M, D'Andrea AD, Garber JE, Garg K, Lim LP, Li M, Paweletz CP, Tayob N, Shapiro GI, Tolaney SM. Lynce F, et al. Clin Cancer Res. 2026 Feb 4;32(3):489-500. doi: 10.1158/1078-0432.CCR-25-0571. Clin Cancer Res. 2026. PMID: 41335237 Clinical Trial.
PURPOSE: We explored the efficacy of PARP inhibition combined with sapacitabine, an orally bioavailable prodrug of the deoxycytidine analog 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine, in patients with germline BRCA1/2-mutated HER2-negative metastatic breast …
PURPOSE: We explored the efficacy of PARP inhibition combined with sapacitabine, an orally bioavailable prodrug of the deoxycytidine analog …
Targeted Treatment of Metastatic Triple-Negative Breast Cancer: A Systematic Review.
Hammershøi Madsen AM, Løvendahl Eefsen RH, Nielsen D, Kümler I. Hammershøi Madsen AM, et al. Breast J. 2024 Jul 11;2024:9083055. doi: 10.1155/2024/9083055. eCollection 2024. Breast J. 2024. PMID: 39742383 Free PMC article.
INTRODUCTION: Triple-negative breast cancer (TNBC) is a subgroup of breast cancer characterized by the absence of estrogen and the human epidermal 2 receptor and also a lack of targeted therapy options. ...METHODS: A systematic search was performed, to …
INTRODUCTION: Triple-negative breast cancer (TNBC) is a subgroup of breast cancer characterized by the absence o …
A Randomized Phase 2 Study of Neratinib With or Without Fulvestrant for Patients With HER2-Positive, Estrogen Receptor-Positive Metastatic Breast Cancer.
Morganti S, Chu X, Ballinger TJ, Unni N, Sinclair S, Wesolowski R, Pereslete AM, Lange P, Tayob N, Lin NU, Leone JP, Krop IE, Tolaney SM, Parsons HA. Morganti S, et al. Clin Breast Cancer. 2025 Aug;25(6):566-574.e2. doi: 10.1016/j.clbc.2025.05.009. Epub 2025 May 16. Clin Breast Cancer. 2025. PMID: 40484776 Clinical Trial.
METHODS: In this randomized, open-label, phase 2 clinical trial, patients with ER-positive (ER 10%), HER2-positive metastatic breast cancer were randomized (1:1) to neratinib (240 mg daily) or the same dose of neratinib with fulvestrant. ...Chemother …
METHODS: In this randomized, open-label, phase 2 clinical trial, patients with ER-positive (ER 10%), HER2-positive metastati …
Chemotherapy-free neoadjuvant pembrolizumab combined with trastuzumab and pertuzumab in HER2-enriched early breast cancer (WSG-KEYRICHED-1): a single-arm, phase 2 trial.
Kuemmel S, Graeser M, Schmid P, Reinisch M, Feuerhake F, Volk V, Armeanu-Ebinger S, Schütz L, Kelemen O, Schroeder C, Ossowski S, Jóźwiak K, Kostara A, Scheffen I, Lüdtke-Heckenkamp K, Hilpert F, Kentsch A, Ziske C, Depenbusch R, Braun M, Blohmer JU, Zu Eulenburg C, Christgen M, Bartels S, Kreipe HH, Wuerstlein R, Biehl C, Pelz E, Hartkopf A, Harbeck N, Gluz O; West German Study Group investigators. Kuemmel S, et al. Lancet Oncol. 2025 May;26(5):629-640. doi: 10.1016/S1470-2045(25)00097-X. Lancet Oncol. 2025. PMID: 40318646 Clinical Trial.
BACKGROUND: Accumulating evidence indicates that about 30-40% of patients with HER2-positive early breast cancer might achieve excellent outcomes without chemotherapy. Therefore, we aimed to test the pathological complete response after the addition of pembrolizu …
BACKGROUND: Accumulating evidence indicates that about 30-40% of patients with HER2-positive early breast cancer might achieve …
Phase 2 trial of imprime and pembrolizumab immunotherapy in metastatic triple negative breast cancer patients who have progressed beyond first line chemotherapy.
Stopeck AT, Abu-Khalaf M, Borges V, Chmielowski B, Rao R, Xie B, Dudek AZ, Mina L, O'Shaughnessy J, Chisamore M, Mattson P, Gargano M, Cox J, Osterwalder B, Drees J, Harrison B, Chan ASH, Qiu X, Ottoson N, Bose N, Uhlik M, Graff J, Iglesias J. Stopeck AT, et al. J Immunol. 2025 Jul 1;214(7):1529-1538. doi: 10.1093/jimmun/vkaf079. J Immunol. 2025. PMID: 40338159 Clinical Trial.
The Phase 2 IMPRIME 1 study evaluated the combination of the pathogen-associated molecular pattern (PAMP) Imprime with the immune checkpoint inhibitor (ICI) pembrolizumab as second or later line of treatment (2 L+) for patients with metastatic triple-negative …
The Phase 2 IMPRIME 1 study evaluated the combination of the pathogen-associated molecular pattern (PAMP) Imprime with the imm …
T-cell immune checkpoint inhibition plus hypomethylation for locally advanced HER2-negative breast cancer: a phase 2 neoadjuvant window trial of decitabine and pembrolizumab followed by standard neoadjuvant chemotherapy.
Bear HD, Deng X, Bandyopadhyay D, Idowu M, Jenkins TM, Kmieciak M, Williams M, Archer G, Gwaltney L, Dillon P, Flora D, Stover D, Poklepovic AS, Hackney M, Ross M, Vachhani H, Louie R, McGuire KP, Grover A, Rahman T, Hendrix A. Bear HD, et al. J Immunother Cancer. 2025 Feb 27;13(2):e010294. doi: 10.1136/jitc-2024-010294. J Immunother Cancer. 2025. PMID: 40021215 Free PMC article. Clinical Trial.
We have shown that the DNMTi decitabine augments the effectiveness of immunotherapy using murine triple-negative breast cancer (TNBC) models. The primary objective was to determine whether DNMTi+immune checkpoint blockade would increase stromal TIL (sTIL) in primary …
We have shown that the DNMTi decitabine augments the effectiveness of immunotherapy using murine triple-negative breast cancer …
HDAC inhibitor tucidinostat and metronomic capecitabine plus endocrine therapy for patients with HR-positive HER2-negative advanced breast cancer after CDK4/6 inhibitors treatment: clinical findings and exploratory circulating tumor cell and ctDNA biomarker analyses of a multicenter, phase 2 study (SYSUCC-020 trial).
Wu HL, Xia W, Xu Z, Zhou H, Chen L, Lu Y, Liu X, Pang D, Liu Y, Lu Q, Xu F, An X, Huang J, Jiang K, Zhang J, Cai Y, Hong R, Zheng Q, Wang S. Wu HL, et al. Signal Transduct Target Ther. 2026 Apr 15;11(1):135. doi: 10.1038/s41392-026-02632-5. Signal Transduct Target Ther. 2026. PMID: 41986320 Free PMC article. Clinical Trial.
Treatment options for patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC) that progresses after CDK4/6 inhibitor (CDK4/6i) continue to evolve, and no single regimen has been established …
Treatment options for patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced bre …
30 results